Verona Pharma closer to third phase testing nebulized ensifentrine in certain COPD treatment
Verona Pharma has randomized the last patient in its Phase 2b dose-ranging study evaluating the effect of nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (“COPD”).